Lactase MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy FormBy SourceBy End-use Product

Lactase is a food-grade enzyme preparation that breaks lactose, the natural sugar in milk, into the simpler sugars glucose and galactose, and is supplied to processors as a liquid concentrate or as a powder or granule preparation dosed directly into dairy or applied during fermentation and cheese-making steps. It is produced in a neutral-pH form for direct addition to fresh milk and dairy beverages and in an acid-stable form suited to whey, cheese and other lower-pH processing streams. Buyers are dairy and food processors formulating lactose-free or lactose-reduced products, ingredient and nutraceutical manufacturers building digestive-health supplements, and specialty food producers that need enzymatic lactose hydrolysis instead of physical separation.

The global lactase market is valued at USD 275 million in 2025 and is set to reach USD 497.8 million by 2034, a compound annual growth rate of 6.8% across the 2026-2034 forecast period. The study tracks the market across USD 178 million in 2020, USD 252 million in 2024, USD 294 million in 2026 and USD 382.6 million in 2030.

The type mix shifts over the period. Neutral Lactase is the largest line in 2025 at USD 170.1 million, a 61.85% share, moving to USD 288.7 million and 57.99% by 2034. Acid Lactase grows fastest at 7.95%, taking its share from 38.15% to 42.01%, while Neutral Lactase grows slowest at 6.04%. Acid Lactase take share over the period; Neutral Lactase give it up while still growing in absolute terms.

Cut by application, the largest line is Food Industry: 68% of 2025 revenue, worth USD 187 million, and 64.01% at USD 318.6 million by 2034. Pharmaceutical Industry grows faster at 8.67% against 6.1%, moving from 24% of revenue to 28% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views, not components.

USD 87.6 million of 2025 revenue is generated in Europe, 31.85% of the global total and the largest regional share; it reaches USD 139.4 million by 2034. North America is next at 26.95% and USD 74.1 million, and Middle East and Africa last at 7.31%. Share shifts toward Asia Pacific and Middle East and Africa over the forecast period, so the regional split repays a close reading.

Coverage extends to five regions, two type lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• A forecast-period rate of 6.8% takes the market from USD 275 million in 2025 to USD 497.8 million in 2034, against 9.09% recorded over the 2020-2025 historical period.
• Neutral Lactase is the largest type line at USD 170.1 million in 2025, a 61.85% share, reaching USD 288.7 million and 57.99% of revenue by 2034.
• Acid Lactase is the fastest-growing line at 7.95%, lifting its share from 38.15% in 2025 to 42.01% in 2034 and its revenue from USD 104.9 million to USD 209.1 million.
• Scenario range for 2034 runs from USD 434.4 million in the bear case to USD 564.6 million in the bull case, against a base-case USD 497.8 million, the spread a plan built on this forecast has to absorb.
• Europe holds 31.85% of global revenue in 2025 at USD 87.6 million, the largest of the five regions tracked, and reaches USD 139.4 million by 2034.
• 26.03% of Europe's base-year revenue comes from Germany alone: USD 22.8 million in 2025, rising to USD 36.2 million by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Three movements define the forecast period in the global lactase market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Composition shifts on the type axis. 7.95% against 6.04%: that gap, between Acid Lactase and Neutral Lactase, is the largest on the type axis. Acid Lactase takes its share of revenue from 38.15% to 42.01% while Neutral Lactase gives up ground, from 61.85% to 57.99%. Neither contracts: USD 104.9 million becomes USD 209.1 million, USD 170.1 million becomes USD 288.7 million. What the spread decides is which of them a supplier's revenue is exposed to.

Asia Pacific and Middle East and Africa gain regional share. Asia Pacific moves from 24.87% of revenue in 2025 to 30% in 2034, worth USD 68.4 million rising to USD 149.3 million; Middle East and Africa moves from 7.31% of revenue in 2025 to 8% in 2034, worth USD 20.1 million rising to USD 39.8 million. The remaining regions grow in absolute terms while giving up share: North America at 26.95% moving to 25.01%, Europe at 31.85% moving to 28.01%, Latin America at 9.02% moving to 9%. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

Fifteen years without a discontinuity. Year by year the total runs USD 178 million in 2020, USD 252 million in 2024, USD 275 million in 2025, USD 294 million in 2026, USD 382.6 million in 2030 and USD 497.8 million in 2034. The forecast rate of 6.8% sits against 9.09% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Acid Lactase adds the most incremental growth

Separate the 6.8% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.

The bear case and what drives it

What the bull case turns on

Concentration on the type axis

26.95% of the global lactase market sits in North America in 2025, worth USD 74.1 million and reaches USD 124.5 million by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

25.01% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the type split tracks the global one; 61.85% of 2025 revenue in Neutral Lactase, fastest growth of 7.95% in Acid Lactase. The full report breaks North America out along every axis and by country.

The United States is the largest market within North America, generating USD 57.8 million in 2025 and projected to reach USD 95.9 million by 2034. At 78% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 74.1 million and USD 124.5 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in the United States follows the type mix reported at global level: Neutral Lactase is the largest line at 61.85% of 2025 revenue, moving to 57.99% by 2034, while Acid Lactase grows fastest at 7.95% and takes its share from 38.15% to 42.01%. With 78% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-type revenue for the United States appears on its own in the full report.

The lactase enzyme used in dairy processing and sold as a dietary supplement falls under the Food and Drug Administration's oversight. As a processing aid added to milk or whey, it must be recognized as Generally Recognized As Safe or cleared through the agency's food additive process before commercial use. Supplements containing lactase are governed by the Dietary Supplement Health and Education Act, which places the burden of safety and label accuracy on the manufacturer without requiring premarket approval. Labeling must satisfy FDA nutrition and allergen disclosure requirements, and any enzyme sourced from a newly applied microbial strain needs its own safety substantiation before it can enter commercial supply.

Competition in the United States runs between the suppliers this study tracks: DSM, Novozymes, DuPont, Chr. Hansen Holding, Amano Enzyme, Enzyme Development, SternEnzym, Specialty Enzymes & Biotechnologies, Enzyme Solutions, Advanced Enzymes, Zhongnuo BioTech, Enze Bio, Meihua BioTech and Kono Chem.. Volume sits in Neutral Lactase at 61.85% of 2025 revenue; movement sits in Acid Lactase at 7.95% growth. Per-company positioning and share at country level are in the full report only.

Canada is sized at USD 10.4 million in 2025, rising to USD 16.8 million by 2034; 3.78% of global revenue and 14.04% of North America. It is reported separately from the United States across every segmentation axis in the full report.

31.85% of the global lactase market sits in Europe in 2025, worth USD 87.6 million and reaches USD 139.4 million by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 28.01% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The type mix reported at global level applies here, with Neutral Lactase the largest line at 61.85% of 2025 revenue and Acid Lactase the fastest-growing at 7.95%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

26.03% of Europe's base-year revenue comes from Germany; USD 22.8 million, rising to USD 36.2 million by 2034. 26.03% of the region in the base year makes it the largest market here without making it the region. Set against USD 87.6 million and USD 139.4 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in Germany follows the type mix reported at global level: Neutral Lactase is the largest line at 61.85% of 2025 revenue, moving to 57.99% by 2034, while Acid Lactase grows fastest at 7.95% and takes its share from 38.15% to 42.01%. With 26.03% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Germany by type separately.

In Germany, lactase used as a food enzyme is regulated under the European Union's food enzyme framework, which requires manufacturers to secure authorization confirming the enzyme's safety and its intended technological function before it can be used in dairy processing. Products marketed as food supplements fall under the EU Food Supplements Directive, transposed into German law and enforced by the Bundesamt für Verbraucherschutz und Lebensmittelsicherheit alongside regional food authorities. Labeling must comply with the EU Food Information to Consumers Regulation, covering ingredient declaration, allergen warnings, and nutrition information. Suppliers must also show that manufacturing follows recognized food safety standards such as HACCP-based quality systems before goods reach German retail shelves.

Competition in Germany runs between the suppliers this study tracks: DSM, Novozymes, DuPont, Chr. Hansen Holding, Amano Enzyme, Enzyme Development, SternEnzym, Specialty Enzymes & Biotechnologies, Enzyme Solutions, Advanced Enzymes, Zhongnuo BioTech, Enze Bio, Meihua BioTech and Kono Chem.. Two different problems sit on the same axis: holding Neutral Lactase at 61.85% of 2025 revenue, and taking Acid Lactase while it grows at 7.95%. The commercial size of that position is USD 87.6 million in 2025 and USD 139.4 million by 2034, 31.85% of the global total in the base year.

The Netherlands is sized at USD 15.8 million in 2025, rising to USD 25.1 million by 2034; 5.75% of global revenue and 18.04% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

France is sized at USD 13.1 million in 2025, rising to USD 20.9 million by 2034; 4.76% of global revenue and 14.95% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Asia Pacific holds 24.87% of the global lactase market in 2025, worth USD 68.4 million rising to USD 149.3 million in 2034. Among the five regions it ranks third by revenue in both years.

Share climbs to 30% by 2034, on growth above the market's own 6.8%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Segment composition follows the global pattern: Neutral Lactase largest at 61.85% of 2025 revenue, Acid Lactase fastest at 7.95%. The full report breaks Asia Pacific out along every axis and by country.

USD 23.3 million of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 53.7 million by 2034. At 34.06% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. The region itself runs USD 68.4 million to USD 149.3 million over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Neutral Lactase at 61.85% of 2025 revenue, easing to 57.99% by 2034, and the fastest is Acid Lactase at 7.95%, from 38.15% to 42.01%. Because the country carries 34.06% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-type revenue for China appears on its own in the full report.

Lactase supplied for food processing in China is regulated under the national food safety law overseen by the State Administration for Market Regulation, which requires enzymes used in dairy manufacturing to appear on the approved list of food additives and processing aids maintained through national food safety standards. Products positioned as health supplements instead fall under the health food registration or filing system administered by the same authority together with the National Health Commission, requiring evidence of safety and claimed function before sale. Labeling must follow national food labeling standards, disclosing ingredients, allergen information, and storage conditions. Imported lactase products additionally require customs clearance confirming conformity with these domestic standards.

Competition in China runs between the suppliers this study tracks: DSM, Novozymes, DuPont, Chr. Hansen Holding, Amano Enzyme, Enzyme Development, SternEnzym, Specialty Enzymes & Biotechnologies, Enzyme Solutions, Advanced Enzymes, Zhongnuo BioTech, Enze Bio, Meihua BioTech and Kono Chem.. Two different problems sit on the same axis: holding Neutral Lactase at 61.85% of 2025 revenue, and taking Acid Lactase while it grows at 7.95%. A supplier weighted toward Asia Pacific is competing over a base of USD 68.4 million in 2025 reaching USD 149.3 million by 2034, 24.87% of global revenue at the start of that period.

5.45% of global revenue is generated in India; USD 15 million in 2025, reaching USD 35.8 million in 2034, and 21.93% of Asia Pacific.

Within Asia Pacific, Japan accounts for 17.98% of regional revenue and 4.47% of the global total, worth USD 12.3 million in 2025 and USD 23.9 million by 2034.

Latin America holds 9.02% of the global lactase market in 2025, worth USD 24.8 million on the way to USD 44.8 million by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Share settles at 9% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Segment composition follows the global pattern: Neutral Lactase largest at 61.85% of 2025 revenue, Acid Lactase fastest at 7.95%. The full report breaks Latin America out along every axis and by country.

USD 11.2 million of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 20.2 million by 2034. Its 45.16% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Set against USD 24.8 million and USD 44.8 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Brazil buys along the same lines as the market globally; Neutral Lactase first at 61.85% of 2025 revenue and 57.99% in 2034, Acid Lactase fastest at 7.95% on a share moving from 38.15% to 42.01%. Its 45.16% weight in Latin America means those movements carry straight into the regional totals. Revenue by type for Brazil is reported separately in the full report.

In Brazil, lactase used in food manufacturing or sold as a supplement is regulated by the National Health Surveillance Agency, ANVISA, under its rules governing food enzymes as processing aids and its separate framework for food supplements. A supplier must demonstrate that the enzyme source has been assessed for safety and that its use aligns with permitted technological purposes before it can be applied in dairy production. Supplement formulations require compliance with ANVISA's labeling resolutions, covering nutrition declarations, allergen statements, and claims language, with registration or notification depending on the product's classification. Imported lactase ingredients must also carry documentation confirming their origin and manufacturing standard meets ANVISA's import requirements.

The suppliers tracked in this study (DSM, Novozymes, DuPont, Chr. Hansen Holding, Amano Enzyme, Enzyme Development, SternEnzym, Specialty Enzymes & Biotechnologies, Enzyme Solutions, Advanced Enzymes, Zhongnuo BioTech, Enze Bio, Meihua BioTech and Kono Chem.) compete in Brazil across the type lines above. Volume sits in Neutral Lactase at 61.85% of 2025 revenue; movement sits in Acid Lactase at 7.95% growth. The commercial size of that position is USD 24.8 million in 2025 and USD 44.8 million by 2034, 9.02% of the global total in the base year.

2.69% of global revenue is generated in Mexico; USD 7.4 million in 2025, reaching USD 13.4 million in 2034, and 29.84% of Latin America.

Middle East and Africa holds 7.31% of the global lactase market in 2025, worth USD 20.1 million and reaches USD 39.8 million by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

Its share rises to 8% over the forecast period, so the region grows faster than the market's 6.8% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Neutral Lactase largest at 61.85% of 2025 revenue, Acid Lactase fastest at 7.95%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

29.85% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 6 million, rising to USD 11.9 million by 2034. At 29.85% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 20.1 million and USD 39.8 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Neutral Lactase at 61.85% of 2025 revenue, easing to 57.99% by 2034, and the fastest is Acid Lactase at 7.95%, from 38.15% to 42.01%. Its 29.85% weight in Middle East and Africa means those movements carry straight into the regional totals. Per-type revenue for Saudi Arabia appears on its own in the full report.

Lactase products sold in Saudi Arabia fall under the Saudi Food and Drug Authority, which regulates both food enzymes used in dairy processing and supplement formulations marketed directly to consumers. A supplier must register the product and demonstrate conformity with technical regulations issued through the Gulf Standardization Organization, covering enzyme purity, permitted sources, and labeling content. Packaging must carry Arabic language labeling disclosing ingredients, allergen warnings, and storage instructions consistent with SFDA requirements. Enzymes derived from microbial or animal sources must also meet halal compliance expectations before distribution, and importers are responsible for maintaining certificates confirming the product's regulatory status at the point of entry.

DSM, Novozymes, DuPont, Chr. Hansen Holding, Amano Enzyme, Enzyme Development, SternEnzym, Specialty Enzymes & Biotechnologies, Enzyme Solutions, Advanced Enzymes, Zhongnuo BioTech, Enze Bio, Meihua BioTech and Kono Chem. are the suppliers covered in Saudi Arabia. Two different problems sit on the same axis: holding Neutral Lactase at 61.85% of 2025 revenue, and taking Acid Lactase while it grows at 7.95%. The commercial size of that position is USD 20.1 million in 2025 and USD 39.8 million by 2034, 7.31% of the global total in the base year.

South Africa is sized at USD 5 million in 2025, rising to USD 10 million by 2034; 1.82% of global revenue and 24.88% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Form, Source, End-Use Product, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.